- Home
- PTMN vs ADCT Comparison
PTMN vs ADCT Comparison
Compare PTMN & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTMN
- ADCT
- Stock Information
- Founded
- PTMN 2006
- ADCT 2011
- Country
- PTMN United States
- ADCT Switzerland
- Employees
- PTMN N/A
- ADCT N/A
- Industry
- PTMN Finance: Consumer Services
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- PTMN Finance
- ADCT Health Care
- Exchange
- PTMN Nasdaq
- ADCT Nasdaq
- Market Cap
- PTMN 142.6M
- ADCT 131.8M
- IPO Year
- PTMN N/A
- ADCT 2020
- Fundamental
- Price
- PTMN $12.29
- ADCT $1.34
- Analyst Decision
- PTMN Hold
- ADCT Strong Buy
- Analyst Count
- PTMN 1
- ADCT 5
- Target Price
- PTMN $14.00
- ADCT $7.75
- AVG Volume (30 Days)
- PTMN 68.2K
- ADCT 330.2K
- Earning Date
- PTMN 05-08-2025
- ADCT 05-09-2025
- Dividend Yield
- PTMN 17.63%
- ADCT N/A
- EPS Growth
- PTMN N/A
- ADCT N/A
- EPS
- PTMN N/A
- ADCT N/A
- Revenue
- PTMN $62,432,000.00
- ADCT $70,837,000.00
- Revenue This Year
- PTMN N/A
- ADCT $6.82
- Revenue Next Year
- PTMN $4.14
- ADCT $18.56
- P/E Ratio
- PTMN N/A
- ADCT N/A
- Revenue Growth
- PTMN N/A
- ADCT 1.84
- 52 Week Low
- PTMN $11.60
- ADCT $1.05
- 52 Week High
- PTMN $20.84
- ADCT $5.17
- Technical
- Relative Strength Index (RSI)
- PTMN 32.98
- ADCT 48.59
- Support Level
- PTMN $11.60
- ADCT $1.13
- Resistance Level
- PTMN $12.58
- ADCT $1.36
- Average True Range (ATR)
- PTMN 0.51
- ADCT 0.09
- MACD
- PTMN 0.14
- ADCT 0.03
- Stochastic Oscillator
- PTMN 49.29
- ADCT 90.32
About PTMN Portman Ridge Finance Corporation
Portman Ridge Finance Corp Inc is a non-diversified closed-end investment company. The company originates, structures, and invests in secured term loans, bonds or notes, and mezzanine debt primarily in privately-held middle market companies but may also invest in other investments such as loans to publicly traded companies, high-yield bonds, and distressed debt securities. The company's investment objective in the Debt securities portfolio is to generate current income and, to a lesser extent, capital appreciation from the investments in senior secured term loans, mezzanine debt, and selected equity investments in privately-held middle market companies.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.